Trials / Completed
CompletedNCT07110441
Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers
A Phase 1, Open Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Genfit · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1, Open-Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy Subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Single Dose G1090N | Subjects will receive single ascending doses of G1090N up to 1200mg. |
| DRUG | Multiple dosing of G1090N | Subjects will receive multiple ascending doses of G1090N up to 1200mg twice daily for 7 consecutive days. |
Timeline
- Start date
- 2025-08-26
- Primary completion
- 2025-12-01
- Completion
- 2025-12-03
- First posted
- 2025-08-07
- Last updated
- 2026-01-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07110441. Inclusion in this directory is not an endorsement.